Nifty’s indicative price plunged 2% in two seconds during the closing auction session on monthly expiry, before recovering sharply. Analyst...

Indian equities gained on Monday as cooling oil prices and positive global cues lifted sentiment. Sensex rose 564 points to 74,859, while N...

Mankind Pharma's shares are in focus following a 16.5% YoY decline in Q3 net profit to Rs 385 crore, despite strong revenue growth of 24%. ...

Mankind Pharma witnessed a 29% surge in consolidated net profit, reaching Rs 658.88 crore in the second quarter, ending September 2024. Thi...

Mankind Pharma Q1 Results: Revenue from operations for the same period increased by 12% year-on-year (YoY) to Rs 2,893 crore, up from Rs 2,...

Mankind Pharma on Wednesday reported 62% year-on-year (YoY) jump in net profit to Rs 477 crore in Q4FY24 led by strong domestic formulation...

Mankind Pharma Q4 Results: The revenue from operations stood at Rs 2,441 crore versus Rs 2,053 crore reported in the year-ago period. Its b...

Mankind Pharma on Wednesday reported a 56% year-on-year (YoY) jump in net profit to Rs 460 crore in Q3FY24 led by strong domestic formulati...

Mankind Pharma Q3: Domestic revenue grew 20% YoY to Rs 2,400 crore, while exports more than doubled to Rs 207 crore. The strong domestic re...

Operating profit, calculated as earnings before interest, taxes, depreciation and amortisation (EBITDA) for the quarter surged 43% YoY to R...

The company reported net profit of Rs 193 crore during the corresponding period of the previous year. Revenue from Operations at Rs 2,053 c...

For FY23, the company reported a 11% drop in consolidated net profit to Rs 1,282 crore, despite a 12.4% growth in revenue to Rs 8,749 crore.

Shares of Mankind Pharma fell more than 6%, a day after its listing on the Indian stock exchanges at a premium. The company's IPO was the l...

At Tuesday's closing price, Mankind Pharma was valued at a price-to-earnings ratio of 43 times its FY22 earnings. Mankind is now India's fi...

The IPO, valued at Rs 4,326 crore, received an overwhelming response, being subscribed for 15.32 times due to interest from qualified insti...

Mankind Pharma is set to list on May 9 with a premium of Rs 120 apiece according to grey market trends. The company is valued at a price-to...

Business: Unlike its peers, Mankind Pharma started in rural India and is now expanding to urban India. The company earns 97% of its revenue...